- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer
- Interventions
- Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy
- Procedure
- Lead sponsor
- University Medical Center Nijmegen
- Other
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2040
- U.S. locations
- 11
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–2
of 2
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adrenal Cortical Cancer, Brain Cancer, Breast Cancer, CNS Cancer, Colon Cancer, HEENT Cancer, Hodgkin's Disease, Kaposi's Sarcoma, Liver Cancer, Lung Cancer, Non-Hodgkin's Lymphoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Sarcoma, Squamous Cell Carcinoma, Thyroid Cancer
- Interventions
- Proton-decoupled 31P MRS at 1.5T, 1H Spectroscopy at 1.5T and 3T
- Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 582 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York